Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569–575.
79.
Green MC, Hortobagyi GN. Adjuvant chemotherapy for breast cancer. Langenbecks Arch Surg 2002;387:109–116.
80.
Murphy GP, Lawrence W, Lenhard RE, eds. American Cancer Society textbook of clinical oncology. Atlanta, GA: American Cancer Society, 1995:213.
81.
Brezden C, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695–2701.
82.
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826.
83.
Rosen PP, Groshen S, Kinne DW, et al. Factors inﬂuencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993;11:2090–2100.
84.
Rapiti E, Fioretta G, Verkooigen HM, et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer 2005;41:1446–1452.
85.
Trudeau ME, Pritchard KI, Chapman JA, et al. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat 2005;89:35–45.
86.
Kollias J, Elston CW, Ellis IO, et al. Early-onset breast cancer— histopathological and prognostic considerations. Br J Cancer 1997;75:1318–1323.
87.
Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with node-positive breast cancer. J Natl Cancer Inst 1998;90:1361–1370.
88.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783– 792.
89.
Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.
90.
Smith I, Procter M, Gelber RD, et al. HERA study team. 2year follow-up of trastuzumab after adjuvant chemotherapy in
HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.
91.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672.
92.